Search

Displaying results 4011 - 4020 of 5897 in total
  1. Drug

    Covax-19™

    go.drugbank.com/drugs/DB15846
    Investigational

    As of June 2020, the vaccine is in Phase 1 trials to evaluate safety and immune responses (NCT04428073). … Phase 2 and 3 trials are planned for September 2020, and the vaccine is expected to launch early in 2021.

  2. Drug

    Ginsenoside Rg1

    go.drugbank.com/drugs/DB06750
    ExperimentalNutraceutical

    Because ginsenosides appear to affect multiple pathways, their effects are complex and difficult to isolate. Rg1 Appears to be most abundant in Panax ginseng (Chinese/Korean Ginseng).

  3. Drug

    TST10088

    go.drugbank.com/drugs/DB05151
    Experimental

    TST10088 has been designed and engineered by Twinstrand to contain a peptide switch that is specifically cleaved by the matrix metalloproteinases which are known to be involved in tumor growth and metastasis … TST10088 is a recombinant variant of a plant toxin belonging to the family of class II ribosome inactivating proteins.

  4. Drug

    MB07811

    go.drugbank.com/drugs/DB05192
    Investigational

    MB07811 is the first of a novel class of product candidates discovered by Metabasis designed to lower serum cholesterol and triglycerides. … The combination of selectivity for the beta form of the receptor, liver targeting and other structural characteristics that limit extra-hepatic activity is designed to provide significant efficacy while

  5. Drug

    Recombinant Bacterial ACE2 Receptors-like Enzyme

    go.drugbank.com/drugs/DB15741
    Investigational

    ._ The molecule, an Angiotensin Converting Enzyme 2 (ACE2)-like enzyme, shares structural similarities to the mammalian ACE2. B38-CAP is an ACE2-like enzyme which decreases angiotensin II levels.

  6. Drug

    APT3111

    go.drugbank.com/drugs/DB06390
    Experimental

    APT3111 is an investigational drug used to treat PNH (paroxysmal nocturnal haemoglobinurea).

  7. Drug

    GPI-0100

    go.drugbank.com/drugs/DB05929
    Investigational

    The GPI-0100 adjuvant, which has been shown to significantly enhance the immune response with a variety of vaccines, has been shown to have good overall performance characteristics on safety and efficacy

  8. Drug

    AT1022

    go.drugbank.com/drugs/DB04995
    Experimental

    AT1022 is a hydromorphone skin patch designed to provide rapid and sustained delivery of a potent opiate for the management of severe pain. … AT1022 incorporates PassPort(TM) system, developed to deliver protein and peptide drugs, small-molecule drugs, genes and vaccines across the skin for local and systemic effect.

  9. Drug

    R450

    go.drugbank.com/drugs/DB05469
    Experimental

    Phase IIa data for the drug show it reduced the number of incontinent episodes compared to placebo with minimal cardiovascular effects. … R450 is an alpha 1 antagonist that acts to tighten the muscle tone in the bladder. It is being considered for treatment of stress-related urinary incontinence.

  10. Drug

    NTLA-2002

    go.drugbank.com/drugs/DB17597
    Investigational

    It is an investigational therapy designed to knock out the target gene kallikrein B1 (KLKB1) to reduce plasma kallikrein activity, thereby preventing hereditary angioedema attacks.[L45738]